Cipla Limited
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
20
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for Stabilized liquid fosaprepitant formulations (US 10,307,432) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Feb 27, 2027The maintenance fee for Ketorolac for the treatment of cancer (US 10,391,080) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 1 fee due Mar 24, 2027The maintenance fee for Pharmaceutical antiretroviral composition (US 10,420,727) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Thienopyridine derivative for the treatment of hepatitis C infections (US 10,471,048) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 2 fees due Jun 3 to 10, 2027 · next Jun 3
- 1 fee due Jul 5, 2027The maintenance fee for Antiviral phosphonate analogues and process for preparation thereof (US 9,227,990) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Antibacterial aminoglycoside analogs (US 9,266,919) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Stable pharmaceutical formulations of pemetrexed (US 11,931,362) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
- 1 fee due Nov 17, 2027The maintenance fee for Anti-retroviral combination (US 9,339,470) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 20 US 12,770,533 Methods and Systems for Simulating Deposition of Inhaled Drug on Lungs
- 1 term has ended since Aug 23, 2026
- Sep 11 US 10,071,062 Methods for the Treatment of Hepatitis C · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,403,844 | Rifaximin In force · Medium confidence | In force | Medium confidence | |
| US 9,877,953 | Rifaximin In force · Low confidence | In force | Low confidence | |
| US 10,702,505 | Rifaximin In force · Low confidence | In force | Low confidence | |
| US 12,109,200 | Rifaximin In force · Low confidence | In force | Low confidence | |
| US 8,822,424 | Antibacterial aminoglycoside analogs In force · USPTO record | In force | USPTO record | |
| US 9,266,919 | Antibacterial aminoglycoside analogs In force · USPTO record | In force | USPTO record | |
| US 9,688,711 | Antibacterial aminoglycoside analogs In force · USPTO record | In force | USPTO record | |
| US 11,117,915 | Antibacterial aminoglycoside analogs In force · USPTO record | In force | USPTO record | |
| US 8,633,234 | Rifaximin In force · High confidence | In force | High confidence | |
| US 9,993,560 | Rifaximin Complexes In force · High confidence | In force | High confidence |
Also on record, not counted in the 66: 3 patents in force now held by others · 104 lapsed for an unpaid fee · 29 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 7 abandoned · 100 no status recorded
Showing 1 to 10 of 112, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/892,191 | Synthesis of Antibacterial Aminoglycoside Analogs | Sep 20, 2024 | Pending |
| 18/648,027 | Apr 26, 2024 | No status recorded | |
| 18/142,909 | May 3, 2023 | No status recorded | |
| 18/301,643 | Apr 17, 2023 | No status recorded | |
| 17/974,804 | Oct 27, 2022 | No status recorded | |
| 17/950,642 | Sep 22, 2022 | No status recorded | |
| 18/691,556 | Solid State Forms of Relugolix | Aug 17, 2022 | Pending |
| 17/724,554 | Apr 20, 2022 | No status recorded | |
| 18/282,007 | Long Acting Injectable Compositions of Cariprazine or its Pharmaceutically Acceptable Salts | Mar 15, 2022 | Abandoned |
| 18/548,691 | Solid State Forms of 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC Acid or Its Pharmaceutically Acceptable Salts and Polymorphs Thereof | Feb 25, 2022 | Pending |
10 of 112 applications shown.
Pro members see all 112 published applications.